RecruitingNot ApplicableNCT07390864

Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy

Intramyometrial Ergometrine Injection Versus Intramyometrial Carbetocin Injection to Decrease Blood Loss During and After Abdominal Myomectomy: A Randomized Clinical Trial

Sponsor

Cairo University

Enrollment

40 participants

Start Date

Jan 18, 2026

Study Type

INTERVENTIONAL

Conditions

Myoma;Uterus

Summary

The goal of this randomized clinical trial is to determine whether intramyometrial ergometrine injection or intramyometrial carbetocin injection is more effective in reducing blood loss during and after abdominal myomectomy in women undergoing surgery for symptomatic uterine fibroids. The main questions it aims to answer are: Does intramyometrial ergometrine reduce intraoperative and postoperative blood loss during abdominal myomectomy? Does intramyometrial carbetocin reduce intraoperative and postoperative blood loss during abdominal myomectomy? Is there a difference between the two drugs in the need for blood transfusion and postoperative hemoglobin drop? Researchers will compare intramyometrial ergometrine injection with intramyometrial carbetocin injection to see which intervention is more effective in controlling surgical bleeding and improving surgical outcomes. Participants will: Undergo abdominal myomectomy for uterine fibroids Receive either intramyometrial ergometrine or intramyometrial carbetocin during surgery Be monitored for intraoperative blood loss, postoperative blood loss, hemoglobin changes, and need for blood transfusion

Eligibility

Sex: FEMALEMin Age: 25 YearsMax Age: 48 Years

Plain Language Summary

Simplified for easier understanding

This trial is comparing two drugs — ergometrine and carbetocin — to see which one better reduces blood loss during a fibroid removal surgery called a myomectomy. Uterine fibroids are noncancerous growths in the womb that can cause heavy bleeding and pain. Heavy bleeding is a major risk during this surgery, and these drugs help the uterus contract to limit blood loss. **You may be eligible if...** - You are a woman aged 25 to 48 - Your BMI is under 35 - You have been diagnosed with uterine fibroids causing symptoms (heavy periods, pelvic pain, or pressure) - Your fibroids are inside the uterine wall (FIGO types 3–6) and the largest is no more than 20cm - You are scheduled for an abdominal fibroid removal surgery **You may NOT be eligible if...** - You have fibroids that grow into the uterine cavity or on a stalk (FIGO types 0, 1, 2, or 7/8) - You have a history of pelvic infections, previous uterine surgery, or blood clotting disorders - You have cardiovascular disease, uncontrolled high blood pressure, or are allergic to these medications - You are pregnant or plan to become pregnant before the study ends Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMethylergometrine (Intramyometrial Injection)

Methylergometrine maleate is administered as an intramyometrial injection diluted in normal saline and injected circumferentially around the myoma before uterine incision during abdominal myomectomy to induce sustained uterine contraction and reduce surgical blood loss.

DRUGCarbetocin (Intramyometrial Injection)

Carbetocin is administered as an intramyometrial injection diluted in normal saline and injected circumferentially around the myoma before uterine incision during abdominal myomectomy to promote sustained uterine contraction and reduce intraoperative and postoperative blood loss.